AUG 17, 2019 11:23 AM PDT

How Does Ecstasy Treat PTSD?

WRITTEN BY: Annie Lennon

Conventionally, Post Traumatic Stress Disorder (PTSD) is treated via talk therapy, with the aim of getting patients to open up about their trauma and rewire how they associate to it. Although successful in many cases, certain varieties of the disorder are unresponsive to traditional therapy, and so require other treatments. Treatments involving ecstasy (or MDMA) have so far proven effective. But how? 

To treat PTSD, ecstasy is used as a facilitator for talk therapy. First synthesized in 1912, its therapeutic benefits were studied in the 1970’s until it designation as a Schedule 1 drug in 1985, due to its popularity as a recreational drug (Stone: 2019). In recent years however, clinical studies have demonstrated its utility in treating otherwise untreatable cases of PTSD. The first of such clinical studies was conducted in 2010, and had impressive results.

For the study, researchers randomly assigned 20 people with chronic PTSD (refractory to both psychotherapy and psychopharmacology) to psychotherapy either with an ecstasy component or an inactive placebo. Administered during two 8-hour sessions, both groups also received preparatory and follow-up non-drug talk therapy. 

At a two-month follow up after finishing treatment, the researchers found that 83% of those who had taken ecstasy saw significant improvements in their symptoms, whereas the same was only seen in 25% of the placebo group. In addition to this, neither group experienced serious drug-related events, negative neurocognitive effects, or significant increases in blood pressure. 

These results of course brought more interest into ecstasy’s potential to treat PTSD, with Phase 3 clinical trials currently underway to develop MDMA-assisted psychotherapy for PTSD into an FDA-approved prescription treatment by the end of 2021(MAPS: 2019). But, given the substance’s reputation for depressive come-downs due to its serotonin-depleting effects, how does it enhance therapeutic outcomes (Lennon: 2019)? 

MDMA causes large increases in several neurotransmitters in the brain, including serotonin, known to contribute to general feelings of wellbeing and happiness. It also increases the release of oxytocin, known to affect how people respond to facial expressions. Research has shown that those with higher levels of oxytocin are less likely to interpret facial expressions as angry and threatening (Miller: 2016). Coupled with the general feelings of wellbeing and connection that the substance induces, this means that people with PTSD, who tend to be hypervigilant for threats, are able to better relax and thus more easily trust their therapist, making them more susceptible to effective treatment.

What’s more, through brain imaging techniques, the substance has been shown to reduce blood flow to the amygdala and the hippocampus, lessening the emotional response people have when accessing traumatic memories, thus making them easier to confront and overcome with the aid of a therapist (Nutt: 2018). 

To conclude, ecstasy is used to treat PTSD as a part of talk therapy. Under the oversight of specially-trained therapists the substance works by allowing patients to feel more at ease accessing traumatic memories and discussing them with their therapists. Although still under research, MDMA-assisted therapy so far has seen much success, especially in treating those with otherwise untreatable trauma. 




Stone, Will: NPR 


Lennon, Annie: Labroots 

Nutt, David: Psychopharmacology Institute 

Miller, Sara G.: Live Science 

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
NOV 11, 2019
NOV 11, 2019
The Mechanism of Lysostaphin, a MRSA-Killing Enzyme, is Revealed
This study can help inform the development of new treatments for antibiotic-resistant microbes....
NOV 11, 2019
NOV 11, 2019
The Women Who Can Smell Without Olfactory Bulbs
Until now, it has been commonly accepted that our sense of smell depends on the transmission of olfactory information from the nose to the olfactory bulb i...
NOV 24, 2019
Drug Discovery & Development
NOV 24, 2019
The Fight Against Lethal Childhood Brain Cancers
Scientists used studies on cell and animal models to reveal insights into lethal childhood brain cancers and find promising drug therapeutics. The deadly c...
DEC 20, 2019
Genetics & Genomics
DEC 20, 2019
Can We Cure Down's Syndrome with Gene Therapy?
Down’s Syndrome (DS) is a genetic disorder brought on by the presence of all of part of a third copy of chromosome 21. Linked to delays in physical g...
JAN 02, 2020
Drug Discovery & Development
JAN 02, 2020
FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer
In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer dr...
JAN 16, 2020
Drug Discovery & Development
JAN 16, 2020
Fatty Acid Supplement Repairs Brain After Stroke in Mice
Researchers have found that supplements containing short chain fatty acids (SCFAs) may be able to help the brain recover from having a stroke. This comes a...
Loading Comments...